Alyeska Investment Group’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Alyeska Investment Group’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-150,000	Closed	-$1.49M	–	603
2022 Q2	$1.49M	Hold	150,000	–	–	0.02%	434
2022 Q1	$1.48M	Hold	150,000	–	–	0.02%	460
2021 Q4	$1.48M	Hold	150,000	–	–	0.02%	478
2021 Q3	$1.46M	Hold	150,000	–	–	0.02%	550
2021 Q2	$1.45M	Buy	150,000 +60,000	+67%	+$583K	0.02%	558
2021 Q1	$875K	Buy	+90,000	New	+$872K	0.01%	607

Other funds holding BIOT

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

RiverPark Advisors New York $219M AUM 14.89% 1-Year Est. Return

Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alyeska Investment Group's BIOT Position: Q3 2022 in Review

Alyeska Investment Group sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q3 2022, closing a stake of 150,000 shares — an estimated $1.49M sold.

Alyeska Investment Group first reported a position in BIOT in Q1 2021 and held it in 6 quarters. The position peaked at $1.49M in Q2 2022. 69 funds tracked by Wall St. Rank hold BIOT as of Q3 2022.

Alyeska Investment Group reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Alyeska Investment Group sold 150,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q3 2022, an estimated $1.49M.
Alyeska Investment Group first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 6 quarters.
Alyeska Investment Group's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.49M in Q2 2022.
69 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q3 2022.

Based on Alyeska Investment Group's 13F filing for Q3 2022, filed 14 Nov 2022.